On March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, reported that its management team will attend and take part in 1-on-1 meetings with potential business partners at the following meetings (Press release, Enterome, MAR 10, 2023, View Source [SID1234628527])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• Glioblastoma Drug Development Summit – March 14-16 in Boston (MA), US
• BIO-Europe Spring – March 20-22 in Basel, Switzerland
• MATWIN’s MEET2WIN – May 11-12 in Bordeaux, France

Enterome’s CEO, Pierre Belichard, will present an overview of the Company and take part in 1-
on-1 meetings with potential investors at the following conferences:
• BioTrinity 2023 – April 25-26 in London, UK
• Bio€quity Europe 2023 – May 14-16 in Dublin, Ireland